Current Collaborations and Initiatives

Lupus Therapeutics has been involved in some of the most important breakthroughs in lupus research and is helping to guide future breakthroughs.

Current/Ongoing Partner Studies

Study Name: Abbvie SELECT-SLE

Phase 3, SLE

Up to 20 LuCIN sites (U.S. and Canada)

Recruiting

Study Name: Biogen TOPAZ-1

Phase 3, SLE

10 LuCIN sites (U.S. and Canada)

Recruiting

Study Name: Biogen TOPAZ-2

Phase 3, SLE

8 LuCIN sites (U.S. and Canada)

Recruiting

Study Name: BMS POETYK-1 SLE

Phase 3, SLE

15 LuCIN sites (U.S. and Canada)

Recruiting

Study Name: BMS POETYK-2 SLE

Phase 3, SLE

13 LuCIN sites (U.S. and Canada)

Recruiting

Study Name: Novartis SIRIUS SLE 1

Phase 3, SLE

Up to 11 LuCIN sites (U.S. and Canada)

Recruiting

Study Name: Novartis SIRIUS SLE 2

Phase 3, SLE

4 LuCIN sites (U.S. and Canada)

Recruiting

Study Name: UCB Phoenycs Fly

UCB

Phase 3, SLE

Up to 30 LuCIN sites (U.S. and Canada)

Active, Not Recruiting

Study Name: UCB PHOENYCS GO

UCB

Phase 3, SLE

27 LuCIN sites (U.S. and Canada)

Enrollment Ended

Study Name: Novartis SIRIUS LN

Phase 3, LN

Up to 15 LuCIN sites (U.S. and Canada)

Recruiting

Study Name: Biogen AMETHYST

Phase 2, 3, CLE

16 LuCIN sites (U.S. and Canada)

Recruiting

Study Name: Zenas BioPharma SunStone

Zenas BioPharma

Phase 2, SLE

Up to 16 LuCIN sites (U.S. and Canada)

Recruiting

Study Name: VIBRANT

Phase 2, LN

15 LuCIN sites (U.S. and Canada)

Recruiting

Current/Ongoing LRA-Sponsored Studies

Study Name: ACE-2020

Phase 2, SLE

6 LuCIN sites (U.S. and Canada)

Recruiting

Study Name: Lupus Landmark

Phase NA, SLE

Up to 24 LuCIN sites (U.S. and Canada)

Recruiting

Current Collaborations

Adicet Bio

Adicet Bio

ADI-001 (Allogeneic Gamma Delta CAR T Cell Therapy)

Phase 1, SLE and LN

Clinical Services

Artiva Allogeneic NK

Allogeneic, Non-genetically Modified Natural Killer Cells

AB-101-03 Phase 1

Advisory/Clinical Services

BMS CAR-T

CD19-Targeted Nex-T Chimeric Antigen Receptor (CAR) T Cells

CA061-1001 Phase 1

Cabaletta Bio CAR T Therapy

CABA-201, An Autologous CD19-Chimeric Antigen Receptor T cells (CAR T) Therapy, SLE and LN

CAB-201-001 Phase 1/2 Trial

Advisory/Clinical Services

Caribou Biosciences

CB-010, an Allogeneic Anti-CD19 CAR-T Cell Therapy with a PD-1 Knockout for LN and ERL

GALLOP Phase 1 Trial

Advisory/Clinical Services

Century Therapeutics CAR NK Cell Therapy

Century Therapeutics

CNTY-101: Allogeneic iPSC-derived CD19-CAR NK Cells

CALiPSO-1, Phase 1, Moderate to Severe SLE

Clinical Services

Cullinan Therapeutics

Cullinan Therapeutics

CLN-978, a CD19xCD3 bispecific T cell engager

Phase 1b, SLE

Advisory/Clinical Services

EMD Serono M5049 WILLOW 

Toll-like receptor (TLR) 7/8 Inhibitor

Phase 2, SLE and/or CLE

Fate Stem Cell Therapy

Induced Pluripotent Stem Cell (iPSC)

Advisory/Clinical Services

GlaxoSmithKline

GSK2857914 Belantamab (monoclonal antibody)

GSK Study: 221615, Phase 1b, SLE

GlaxoSmithKline

GSK4527363 (monoclonal antibody) and belimumab

GSK Study: 221458, Phase 1b, SLE

Clinical Services

iCell Gene Therapeutics

Advisory Services

Nkarta CAR NK

Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK)

NKX019-102 Phase 1

Advisory/Clinical Services

Ventus c-GAS

cGAS/STING Inhibitor

Advisory Services

Historical/Completed Studies

Study Name: RIFLE

Phase 4, SLE

21 LuCIN sites (U.S. and Canada)

Enrollment Ended

Study Name: Janssen LOTUS

Phase 3, SLE

27 LuCIN sites (U.S. and Canada)

Terminated

Study Name: VeraTx COMPASS

Phase 3, LN

13 LuCIN sites (U.S. and Canada)

Terminated

Study Name: BMS Paisley SLE

Phase 2, SLE

21 LuCIN sites (U.S. and Canada)

Enrollment Ended

Study Name: AMG570

Phase 2, SLE

16 LuCIN sites (U.S. and Canada)

Terminated

Study Name: AMG592

Phase 2b, SLE

10 LuCIN sites (U.S. and Canada)

Terminated

Study Name: Celgene CC-220

Phase 2, SLE

22 LuCIN sites (U.S. and Canada)

Enrollment Ended

Study Name: EMD Serono M2591

Phase 2, SLE

8 LuCIN sites (U.S. and Canada)

Terminated

Study Name: Lilly BT01

Phase 2, SLE

4 LuCIN sites (U.S. and Canada)

Terminated

Study Name: Lilly ISLAND SLE (KFAJ)

Phase 2, SLE

15 LuCIN sites (U.S. and Canada)

Enrollment Ended

Study Name: VIB7734 RECAST SLE

Phase 2, SLE

7 LuCIN sites (U.S. and Canada)

Enrollment Ended

Study Name: Janssen Orchid

Phase 2, LN

6 LuCIN sites (U.S. and Canada)

Enrollment Ended

Study Name: BMS Paisley LN

Phase 2, LN

18 LuCIN sites (U.S. and Canada)

Enrollment Ended

Study Name: Gilead COSMIC

Phase 2, CLE

7 LuCIN sites (U.S. and Canada)

Recruiting

Study Name: TAK-079

Phase 1b, SLE

10 LuCIN sites (U.S. and Canada)

Enrollment Ended

Study Name: Aker-ORKIDS

Phase NA, SLE

22 LuCIN sites (U.S. and Canada)

Enrollment Ended

Study Name: DIVINE

Phase NA, LN

7 LuCIN sites (U.S. and Canada)

Enrollment Ended

Study Name: VALUE

Phase NA, SLE

10 LuCIN sites (U.S. and Canada)

Enrollment Ended